Status and phase
Conditions
Treatments
About
To determine the overall response rate (CR+PR) of patients with relapsed or refractory multiple myeloma treated with clofarabine.
Full description
To determine the time to response, duration of response, and time to progression of patients treated with clofarabine.
To determine the safety and tolerability of clofarabine in these patients.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Multiple myeloma diagnosed by standard criteria.
Measurable levels of monoclonal protein in serum (>= 0.5 g/dL) or urine (>= 0.2 g/24 hr).
At least 1 prior therapies for multiple myeloma with documented evidence of progression on the most recent treatment.
Age 18 years or older.
ECOG performance status <= 2.
Acceptable organ and marrow function as defined below:
Women of child bearing potential must agree to use adequate contraception prior to study entry and for the duration of study.
Ability to understand and the willingness to sign a written informed consent document.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
8 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal